
LRMR Stock Forecast & Price Target
LRMR Analyst Ratings
Bulls say
Larimar Therapeutics has demonstrated promising clinical outcomes with its lead product candidate, CTI-1601, as indicated by a significant increase in median frataxin (FXN) expression from 2.7 pg/ug at baseline to 13.44 pg/ug at six months, exceeding the levels seen in over 50% of healthy volunteers. Additionally, the company reported a median improvement of -2.20 points in the Modified Friedreich's Ataxia Rating Scale (mFARS), contrasting with a decline for the FACOMS natural history population, further supporting the efficacy of its treatment. These positive clinical data metrics highlight the potential for CTI-1601 to address critical therapeutic needs in patients with Friedreich's ataxia, reinforcing a favorable outlook for the company’s stock.
Bears say
Larimar Therapeutics has faced a substantial decrease in its revenue projections for fiscal year 2029, with estimates dropping from $659 million to $407 million, raising concerns about the company’s growth potential in the Friedreich's ataxia market. Additionally, the median mFARS score change of -2.20 points over one year suggests underwhelming therapeutic performance compared to the FACOMS data, which recorded a +1.00 point change, indicating potential difficulties in demonstrating clinical efficacy. These factors contribute to a negative outlook on the company's financial health and market confidence in its lead product candidate, CTI-1601.
This aggregate rating is based on analysts' research of Larimar Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
LRMR Analyst Forecast & Price Prediction
Start investing in LRMR
Order type
Buy in
Order amount
Est. shares
0 shares